Study drugs make healthy people work harder, not think better

It’s the week before finals, and a roommate with a prescription offers you one of their pills. Half your friends seem to have tried it. The pitch is simple: sharper focus, longer hours, better grades.

The habit is common. A federal survey estimated that 3.94 million Americans aged 12 and older misused a prescription stimulant in 2025, including 978,000 people aged 18 to 25. The controlled research is less flattering. In healthy, rested people the measured gains are small and patchy, and in the most realistic test so far, the drugs made people work longer and do worse.

This article looks at prescription stimulants, the wakefulness drug modafinil and psychedelic microdosing as used by people without a diagnosis who want to think better. Over-the-counter products sold as nootropics, and the unapproved drugs labs have found inside some of them, are covered in the library’s piece on brain-health supplements. ADHD itself, including diagnosis and the stimulant shortage, belongs to the library’s article on executive function.

Who uses study drugs, and why

The National Survey on Drug Use and Health, run by the Substance Abuse and Mental Health Services Administration (SAMHSA), puts past-year misuse of prescription stimulants in 2025 at about 1.4 percent of people 12 and older. Among 18- to 25-year-olds the rate was 2.7 percent, about double the figure for all ages. Teens aged 12 to 17 accounted for 216,000 people. None of the figures changed significantly from 2024.

Why people do it is clearer in an earlier analysis of the same survey. Researchers from the National Institute on Drug Abuse and SAMHSA, led by Wilson M. Compton, examined 2015 and 2016 data from about 102,000 adults. Each year, on average, 16.0 million adults used prescription stimulants, 5.0 million misused them and 0.4 million had a stimulant use disorder. The most common reason for misuse was to stay alert or concentrate, given by 56.3 percent. The most common source was free pills from friends or relatives, at 56.9 percent.

Is everyone on campus doing it?

Campus estimates swing with the survey and the definition. FDA’s 2023 safety communication, summarizing published studies, put past-year nonmedical use at 4.3 percent of college students and 4.1 to 7.5 percent of 18- to 25-year-olds. A 2015 meta-analysis pooled studies to reach 17 percent of college students, but its authors noted that no standard definition of misuse exists, so that figure describes inconsistent surveys rather than a yearly rate. By any of these estimates, most students don’t use them.

What controlled trials in healthy people found

The question sounds simple: does a stimulant make a healthy, rested brain work better than a placebo does? Dozens of lab studies have tried to answer it.

A 2015 meta-analysis led by Irena P. Ilieva at the University of Pennsylvania pooled 48 studies with 1,409 healthy participants taking methylphenidate or amphetamine. It found small but significant gains in inhibitory control, the ability to hold back a reflexive response, and in short-term memory for newly learned material. Effects on delayed memory were medium-sized, but the working-memory and long-term memory results were clouded by publication bias, the tendency for positive studies to get published while null ones sit in file drawers. The authors judged the overall effect on healthy cognition probably modest, and suggested healthy users may be after energy and motivation more than better thinking.

A 2020 series of meta-analyses by Carl A. Roberts and colleagues at the University of Liverpool examined 47 studies of healthy adults who were not sleep-deprived. Modafinil showed an overall standardized effect of 0.12 and methylphenidate 0.21, driven by recall, sustained attention and inhibitory control. Dextroamphetamine showed no effects at all. The authors put it plainly: “There is a user perception that these drugs are effective cognitive enhancers, but this is not supported by the evidence so far.”

What does 0.21 mean? By our arithmetic, the average person on methylphenidate would outscore about 58 percent of people on placebo, against the 50 percent expected by chance. By common statistical convention, that counts as a small effect.

A 2010 systematic review from Charité university hospital in Berlin reached a similar verdict: expectations about methylphenidate and modafinil exceed their actual effects. Methylphenidate improved memory, with no consistent evidence of other gains. Modafinil improved attention in rested people and helped sleep-deprived people stay awake and perform better than placebo. Over longer sleep deprivation, though, repeated doses could not stop performance from sliding, and may have made people overconfident about how well they were doing.

The case for modafinil, stated fairly

The most favorable review is a 2015 look at modafinil by R. M. Battleday and A-K Brem at the University of Oxford, covering studies from 1990 through 2014. On basic tests, modafinil usually improved executive function, the mental skills behind planning and self-control, but only half the studies found better attention or memory, and a few found worse divergent thinking, the open-ended kind that generates many ideas. On more complex assessments, it consistently improved attention, executive function and learning, with no excess of side effects or mood changes. The reviewers also stressed that methods varied widely and that many studies used tests built to detect problems in ill people, not gains in healthy ones.

A smaller, single-blind 2025 study by researchers at the National Institutes of Health hints at where the line falls. Among 37 healthy adults given methylphenidate or placebo, accuracy improved on the easier of two visual tracking tasks, but not significantly on the harder one, and response times did not change significantly. The authors themselves suggest the harder task was not challenging enough to reveal a benefit.

The hard-problem test: more effort, worse work

Most lab studies use simple, repetitive tasks. Real studying and real work look more like puzzles with many moving parts. A 2023 study in Science Advances by Elizabeth Bowman, David Coghill, Carsten Murawski and Peter Bossaerts, of the University of Melbourne and the University of Cambridge, tried to capture that.

Forty healthy volunteers aged 18 to 35, screened by a clinician, each came in four times at least a week apart. In random order, and without knowing which, they got a single dose of methylphenidate, dextroamphetamine, modafinil or placebo, at the high end of clinical doses to mirror non-prescribed use. Then they worked on the knapsack problem: pick from a set of items, each with a weight and a value, to pack the most value under a weight limit. It stands in for everyday choices like buying the most useful things on a budget or planning the stops on a delivery route.

• Same success rate. People found the best answer about half the time, and the drugs didn’t significantly change that.
• Lower value. The solutions people submitted were worth less on the drugs.
• More effort. Time spent rose significantly on methylphenidate and dextroamphetamine, and both drugs increased the number of moves; modafinil’s increases weren’t significant. On methylphenidate, people spent nearly as long on the easiest problems as on the hardest ones under placebo, with nothing to show for it.
• Worse effort. The value gained per move fell on all three drugs, and first attempts became more random.
• Stars fell. People who were above average on placebo tended to drop below average on the drugs. Below-average performers improved, but only because they put in more time.

The authors concluded that the drugs raise motivation while a drop in the quality of effort cancels it out. The limits are real: single doses, 40 people, one kind of task. Still, it tested something closer to real work than most of the literature, and the pattern held for all three drugs.

And grades?

A University of Maryland team led by Amelia M. Arria followed 898 undergraduates without an ADHD diagnosis and took their GPAs from college records. Students who didn’t misuse stimulants in either year saw their GPAs rise significantly from one year to the next. Students who started, stopped or kept using saw no significant change. The researchers couldn’t rule out that use prevented a decline, but users gained no detectable edge over their peers.

Microdosing: the placebo group improves too

Microdosing means taking small, regular amounts of a psychedelic such as LSD or psilocybin, the active compound in so-called magic mushrooms, below the level that causes a full trip. Users report sharper focus, better mood and more creativity. Placebo-controlled studies tell a humbler story.

• Self-blinding at home. In 2021, researchers at Imperial College London gave microdosers online instructions for building placebo control into their own routines, without clinical supervision. Among 191 people who finished, every psychological measure improved over four weeks in the microdose group, the placebo group improved too, and the groups did not differ significantly. Small differences on dosing days could be explained by people figuring out what they had taken. The authors wrote: “The findings suggest that anecdotal benefits of microdosing can be explained by the placebo effect.”
• Guessing drives the effect. A 2022 double-blind study in Argentina of 34 people starting to microdose psilocybin mushrooms found stronger acute effects only in those who correctly guessed they had the active dose. Well-being, creativity and cognition did not improve, and a few small changes pointed toward impairment.
• In the lab. A University of Chicago study published in 2022 gave 56 healthy adults four low doses of LSD or placebo a few days apart. The higher dose produced modest but noticeable drug effects and did not improve mood or performance.
• The 2025 trials. Two double-blind trials led from Leiden University found no significant effect of psilocybin microdosing on thinking or mood measures after correcting for multiple comparisons, and participants stayed blinded. Unpleasant bodily feelings were more common on the active dose. Pooling three trials with 171 people, the same group found one narrow creativity gain, a higher share of original answers on an idea-generation test, and no change on other creativity scores.
• ADHD. A 2025 trial in Switzerland and the Netherlands found repeated low-dose LSD no better than placebo for adult ADHD symptoms.

Two 2026 reviews pulled the field together. A meta-analysis in CNS Drugs covering 24 studies and 3,681 participants found that randomized trials showed minimal effects on cognition, creativity or lasting mood. An umbrella review in the Journal of Psychopharmacology, which combined earlier reviews with heavily overlapping studies, found that the only significant pooled effect was a small decline in cognitive control, the opposite of the popular claim. It also noted that possible cardiovascular signals and long-term risks have not been characterized.

None of this means microdosers imagine their improvement. People in these studies really did feel and score better. So did the people taking placebo. Expectation, fresh attention to routines and the motivation that comes with starting something new are real effects. They just don’t belong to the drug.

The costs that come with the pill

Medical risks

In May 2023, FDA required the boxed warning on every prescription stimulant to be updated so all of them describe the same risks of misuse, abuse, addiction and overdose. The agency noted that overdose risk climbs with higher doses, with crushing and snorting or injecting pills, and with mixing stimulants with alcohol or other drugs such as opioids, and that an overdose can cause a heart attack, stroke or seizures. It also warned that pills from illegal sellers may be fakes containing fentanyl or methamphetamine.

The prescribing information for mixed amphetamine salts, revised in July 2026, adds specifics:

• Sudden death has been reported in people with structural heart problems.
• Stimulants raise blood pressure and heart rate.
• New psychotic or manic symptoms appeared in about 0.1 percent of treated patients in trials, versus none on placebo.
• The drug may lower the seizure threshold.
• It is contraindicated within 14 days of an MAO inhibitor, a class that includes some antidepressants and the antibiotic linezolid, because of the risk of a dangerous blood pressure spike.

Modafinil is often described as the gentle option. Its label says otherwise: rare serious rashes, including Stevens-Johnson syndrome, a life-threatening skin reaction; postmarketing reports of mania, delusions, hallucinations and suicidal thoughts; and weaker hormonal birth control during use and for a month after stopping. It has euphoric effects typical of stimulants. It is approved only for excessive sleepiness from narcolepsy, obstructive sleep apnea or shift work disorder in adults, and for no condition in children.

How these drugs act on brain chemistry often gets squeezed into a dopamine slogan, which the library’s neurotransmitter article takes apart.

For microdosers, the safety record comes only from short, supervised studies using measured doses. Pills and mushrooms bought outside a study come with no supervision and no measured dose.

Legal risks

• Under federal regulations, amphetamine, methylphenidate and lisdexamfetamine are Schedule II controlled substances, modafinil is Schedule IV, and LSD and psilocybin are Schedule I.
• Federal law makes it a crime to distribute a controlled substance except as authorized. For a Schedule II stimulant, the maximum for an individual is 20 years in prison and a $1 million fine, rising to 20 years to life if death or serious injury results. For Schedule IV, it is five years and $250,000.
• In that statute, the only special treatment for giving a drug away without payment covers a small amount of marijuana. Nothing similar exists for stimulants. These are maximums, not typical sentences, and state laws apply as well.
• FDA reports that as many as half of young people with valid stimulant prescriptions are approached by peers to sell or give away their medicine.

Weighing a borrowed pill: what the evidence says

This summary is our own construction from the studies above. It describes evidence, not a recommendation.

The hope	What controlled studies found
Better memory for an exam	Small gains on some memory measures, with signs of publication bias; none for dextroamphetamine in a 47-study analysis
Faster, better problem-solving	More time and effort, lower-quality solutions; strong performers fell furthest
Higher grades	Student users’ GPAs didn’t rise; non-users’ GPAs did
Staying sharp while short on sleep	Modafinil kept sleep-deprived people more awake and sharper than placebo, but repeated doses didn’t stop the slide and may inflate confidence
Creativity or mood from microdosing	Placebo groups improved as much; one narrow creativity score moved

The risks are not evenly spread. Labels flag people with heart conditions, a history of psychosis or bipolar disorder, anyone taking an MAO inhibitor and, for modafinil, anyone relying on hormonal birth control. FDA also warns that pills bought outside a pharmacy may be counterfeit.

When to get help

• Call 911 for chest pain, fainting, a seizure, severe agitation, confusion or hallucinations after a stimulant or an unknown pill.
• Poison help, 1-800-222-1222, connects to a local poison center around the clock for questions about a pill someone took or a possible overdose without emergency signs.
• New suspiciousness, hearing voices or manic behavior in someone taking a stimulant needs prompt medical attention.
• A rash after starting modafinil calls for contacting the prescriber the same day. The label tells prescribers to discontinue the drug at the first sign of rash unless it is clearly unrelated.
• Feeling unable to study or work without a stimulant is worth an evaluation. Whether the cause is ADHD, a sleep problem or depression is a clinician’s question, and the library’s coverage of fatigue sorts out how tiredness and sleepiness differ.
• Trouble cutting back is a substance use question. SAMHSA’s National Helpline, 1-800-662-4357, offers free, confidential treatment referrals 24 hours a day, every day.
• A crash into hopelessness or thoughts of suicide call for the 988 Suicide & Crisis Lifeline: call or text 988, or chat through 988lifeline.org. It also helps with alcohol and drug concerns.
• Prescription holders who keep getting asked for pills can ask their prescriber about safe storage and disposal; FDA advises storing stimulants securely and using drug take-back sites for leftovers.

The takeaway

The best-controlled evidence says prescription stimulants and modafinil change how hard healthy people try, and how confident they feel, more than how well they think. Gains on simple lab tasks are small, gains on hard problems can turn into losses, and student users showed no grade advantage. Microdosing’s benefits largely vanish against placebo. The costs, from addiction and heart risks to counterfeit pills and felony exposure, are documented and fall on the person sharing as well as the person taking. If focus is the real problem, an evaluation of its cause offers something these pills did not.

Sources

1. Substance Abuse and Mental Health Services Administration. “Results from the 2025 National Survey on Drug Use and Health: Detailed Tables, Section 1 (Tables 1.14A and 1.14B).” samhsa.gov
2. U.S. Food and Drug Administration. “FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions (Drug Safety Communication, May 11, 2023).” fda.gov
3. National Library of Medicine, DailyMed. “Mixed amphetamine salts tablets, prescribing information (revised 07/2026).” dailymed.nlm.nih.gov
4. National Library of Medicine, DailyMed. “Modafinil tablets, prescribing information.” dailymed.nlm.nih.gov
5. Legal Information Institute, Cornell Law School. “21 CFR 1308.12, Schedule II.” law.cornell.edu
6. Legal Information Institute, Cornell Law School. “21 CFR 1308.14, Schedule IV.” law.cornell.edu
7. Legal Information Institute, Cornell Law School. “21 CFR 1308.11, Schedule I.” law.cornell.edu
8. Legal Information Institute, Cornell Law School. “21 U.S. Code 841, Prohibited acts A.” law.cornell.edu
9. Health Resources and Services Administration. “Poison Help.” poisonhelp.hrsa.gov
10. Substance Abuse and Mental Health Services Administration. “SAMHSA's National Helpline.” samhsa.gov
11. 988 Suicide & Crisis Lifeline. “988 Suicide & Crisis Lifeline.” 988lifeline.org
12. American Journal of Psychiatry. “Compton WM, Han B, Blanco C, Johnson K, Jones CM. "Prevalence and Correlates of Prescription Stimulant Use, Misuse, Use Disorders, and Motivations for Misuse Among Adults in the United States." Am J Psychiatry, 2018. PubMed. DOI: 10.1176/appi.ajp.2018.17091048.” pubmed.ncbi.nlm.nih.gov
13. Clinical Child and Family Psychology Review. “Benson K, Flory K, Humphreys KL, Lee SS. "Misuse of stimulant medication among college students: a comprehensive review and meta-analysis." Clin Child Fam Psychol Rev, 2015. PubMed. DOI: 10.1007/s10567-014-0177-z.” pubmed.ncbi.nlm.nih.gov
14. Journal of Cognitive Neuroscience. “Ilieva IP, Hook CJ, Farah MJ. "Prescription Stimulants' Effects on Healthy Inhibitory Control, Working Memory, and Episodic Memory: A Meta-analysis." J Cogn Neurosci, 2015. PubMed. DOI: 10.1162/jocn_a_00776.” pubmed.ncbi.nlm.nih.gov
15. European Neuropsychopharmacology. “Roberts CA, Jones A, Sumnall H, Gage SH, Montgomery C. "How effective are pharmaceuticals for cognitive enhancement in healthy adults? A series of meta-analyses of cognitive performance during acute administration of modafinil, methylphenidate and D-amphetamine." Eur Neuropsychopharmacol, 2020. PubMed. DOI: 10.1016/j.euroneuro.2020.07.002.” pubmed.ncbi.nlm.nih.gov
16. Pharmacological Research. “Repantis D, Schlattmann P, Laisney O, Heuser I. "Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review." Pharmacol Res, 2010. PubMed. DOI: 10.1016/j.phrs.2010.04.002.” pubmed.ncbi.nlm.nih.gov
17. European Neuropsychopharmacology. “Battleday RM, Brem AK. "Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review." Eur Neuropsychopharmacol, 2015. PubMed. DOI: 10.1016/j.euroneuro.2015.07.028.” pubmed.ncbi.nlm.nih.gov
18. Journal of Neuroscience. “Yan W, Demiral SB, Tomasi D, et al. "Methylphenidate Promotes a Frontoparietal-Dominant Brain State Improving Cognitive Performance: A Randomized Trial." J Neurosci, 2025. PubMed. DOI: 10.1523/JNEUROSCI.1693-24.2025.” pubmed.ncbi.nlm.nih.gov
19. Science Advances. “Bowman E, Coghill D, Murawski C, Bossaerts P. "Not so smart? 'Smart' drugs increase the level but decrease the quality of cognitive effort." Sci Adv, 2023. PubMed. DOI: 10.1126/sciadv.add4165.” pubmed.ncbi.nlm.nih.gov
20. Addictive Behaviors. “Arria AM, Caldeira KM, Vincent KB, et al. "Do college students improve their grades by using prescription stimulants nonmedically?" Addict Behav, 2017 (online 2016). PubMed. DOI: 10.1016/j.addbeh.2016.07.016.” pubmed.ncbi.nlm.nih.gov
21. eLife. “Szigeti B, Kartner L, Blemings A, et al. "Self-blinding citizen science to explore psychedelic microdosing." eLife, 2021. PubMed. DOI: 10.7554/eLife.62878.” pubmed.ncbi.nlm.nih.gov
22. Translational Psychiatry. “Cavanna F, Muller S, de la Fuente LA, et al. "Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study." Transl Psychiatry, 2022. PubMed. DOI: 10.1038/s41398-022-02039-0.” pubmed.ncbi.nlm.nih.gov
23. Addiction Biology. “de Wit H, Molla HM, Bershad A, Bremmer M, Lee R. "Repeated low doses of LSD in healthy adults: A placebo-controlled, dose-response study." Addict Biol, 2022. PubMed. DOI: 10.1111/adb.13143.” pubmed.ncbi.nlm.nih.gov
24. Neuropharmacology. “Prochazkova L, Marschall J, Lippelt DP, et al. "Cognitive and subjective effects of psilocybin microdosing: Results from two double-blind placebo-controlled longitudinal trials." Neuropharmacology, 2025. PubMed. DOI: 10.1016/j.neuropharm.2025.110722.” pubmed.ncbi.nlm.nih.gov
25. Neuropharmacology. “Prochazkova L, Marschall J, van Elk M, et al. "Microdosing psilocybin and its effect on creativity: Lessons learned from three double-blind placebo controlled longitudinal trials." Neuropharmacology, 2025. PubMed. DOI: 10.1016/j.neuropharm.2025.110732.” pubmed.ncbi.nlm.nih.gov
26. JAMA Psychiatry. “Mueller L, Santos de Jesus J, Schmid Y, et al. "Safety and Efficacy of Repeated Low-Dose LSD for ADHD Treatment in Adults: A Randomized Clinical Trial." JAMA Psychiatry, 2025. PubMed. DOI: 10.1001/jamapsychiatry.2025.0044.” pubmed.ncbi.nlm.nih.gov
27. CNS Drugs. “Meshkat S, Leung M, Meshkat S, et al. "Efficacy and Safety of Psychedelic Microdosing on Psychological Outcomes in Healthy Adults: A Systematic Review and Meta-analysis." CNS Drugs, 2026. PubMed. DOI: 10.1007/s40263-026-01325-5.” pubmed.ncbi.nlm.nih.gov
28. Journal of Psychopharmacology. “Özaydın Y, Canlan Özaydın B. "Classical psychedelic microdosing, mood, and cognitive function: An umbrella review with narrative synthesis." J Psychopharmacol, 2026. PubMed. DOI: 10.1177/02698811261456196.” pubmed.ncbi.nlm.nih.gov